MyFinsight
Home
Blog
About
Issuance of stock in
connection with offerings
$346,217K
Proceeds from exercise of
stock options
$650K
Net cash provided by
financing activities
$325,426K
Canceled cashflow
$21,441K
Net increase
(decrease) in cash and cash...
$282,961K
Canceled cashflow
$42,465K
Issuance costs in
connection with offerings
$21,441K
Paramora warrant
obligation
$9,527K
Stock-based compensation
$9,278K
Accrued expenses and
other current...
$6,494K
Accounts payable
$3,038K
Amortization of right of use
lease asset
$68K
Depreciation of equipment
$11K
Net cash used in
operating activities
-$42,465K
Canceled cashflow
$28,416K
Net loss
-$58,957K
Related party accounts
payable and other...
-$11,559K
Prepaid expenses and
other current assets
$274K
Operating lease
liabilities
-$67K
Other assets,
noncurrent
$23K
Other liabilities,
noncurrent
-$1K
Back
Back
Cash Flow
Damora Therapeutics, Inc. (DMRA)
Damora Therapeutics, Inc. (DMRA)
source: myfinsight.com